Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INCR -- Incara Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (173)	6/28/2002 11:18:40 AM
From: tom pope	Respond to of 196

sloppy crap from Incara Market isn't impressed, in fact it's acting like no one reads Incara releases any more.

To: scaram(o)uche who wrote (173)	7/25/2002 9:59:50 PM
From: mopgcw	Read Replies (1) \| Respond to of 196

messages.yahoo.com For What It's Worth by: keith_dmg Long-Term Sentiment: Strong Buy 07/19/02 10:40 am Msg: 2453 of 2455 The following blurb appears today on ceocast website: "Deligoparin is an ultra-low molecular weight heparin which we’re testing in a phase 2/3 clinical trial for ulcerative colitis. With 127 patients we have not had a single adverse event. We’re seeing an overall response rate that says that it is certainly possible the drug is working, and if our original assumptions in our modeling were right in looking at the placebo response rate then it’s very likely that we’ve the kind of activity we were looking for." Clayton I. Duncan, Incara Pharmaceuticals